Metacrine scores $22 mln Series B
San Diego-based Metacrine, a biotechnology company focused on drug development, has raised $22 million in Series B financing. New Enterprise Associates led the round with participation from return backers ARCH, Polaris, venBio and Alexandria Venture Investments.
7 December 2017•1 min read
